Propranolol Oral Dosing
Pediatric Dosing (Infantile Hemangiomas)
For uncomplicated infants with infantile hemangiomas, start propranolol at 1 mg/kg/day divided into 2-3 doses, then increase after 24 hours to a maintenance dose of 2-3 mg/kg/day. 1, 2
Standard Initiation Protocol
- Starting dose: 1 mg/kg/day in 2-3 divided doses
- Maintenance dose: 2-3 mg/kg/day (optimal efficacy demonstrated at 3 mg/kg/day for 6 months) 1
- Dose escalation: Can increase after minimum 24 hours 2
- Maximum dose: 3 mg/kg/day for non-responders 2
Critical Safety Requirements
Always administer propranolol with or after feeding, and hold doses during times of diminished oral intake or vomiting to prevent hypoglycemia. 1 This is a strong recommendation based on the well-established risk of hypoglycemia-induced seizures in infants.
Modified Dosing for High-Risk Patients
Patients requiring lower initial doses (0.5 mg/kg/day):
- Age < 4 weeks
- Preterm infants
- Low birth weight or faltering growth
- Poor feeding/feeding difficulties
- History of hypoglycemia
- PHACE syndrome (segmental facial hemangiomas with cerebrovascular abnormalities) 2
- Comorbidities: hyperinsulinism, cardiac/respiratory/metabolic/neurological disorders
For PHACE syndrome specifically, start at 0.5 mg/kg/day and obtain brain MRI/MRA before full-dose escalation. If arterial stenosis is present, consult pediatric neurology before increasing doses. 2
Monitoring Requirements
Outpatient initiation (no monitoring needed) if:
- Age > 4 weeks
- Term birth with normal weight
- Established feeds with appropriate weight gain
- No significant comorbidities 2
Inpatient monitoring (2-4 hours with HR/BP every 30 minutes) required for:
- Age < 4 weeks
- Preterm or low weight
- Faltering growth or feeding difficulties
- Significant comorbidities
- Dose increments > 0.5 mg/kg/day 2
Glucose monitoring: Only check in patients at risk (preterm, low weight, poor feeding, history of hypoglycemia) 2
Treatment Duration
- Minimum: 6 months (superior to 3 months) 1
- Optimal: Continue until at least 12 months of age, ideally 12-15 months to minimize rebound growth 1
- Maximum: Most patients don't need treatment beyond 17 months 2
- Discontinuation: Can stop abruptly without tapering 2
Formulation
Use propranolol hydrochloride oral solution 5 mg/5 mL to minimize dosing errors 2
Adult Dosing (Cardiovascular Indications)
For hypertension, start with 80 mg once daily of extended-release propranolol, titrating to 120-160 mg once daily for maintenance. 3
Hypertension
- Initial: 80 mg once daily (extended-release)
- Maintenance: 120-160 mg once daily
- Maximum: Up to 640 mg daily may be required 3
- Titration: Increase gradually; full response may take days to weeks
Angina Pectoris
- Initial: 80 mg once daily (extended-release)
- Maintenance: Average optimal dose 160 mg once daily
- Maximum: 320 mg daily (safety beyond this not established) 3
- Discontinuation: Taper gradually over several weeks to avoid rebound
Migraine Prophylaxis
- Initial: 80 mg once daily (extended-release)
- Effective range: 160-240 mg once daily
- Trial duration: If no response after 4-6 weeks at maximum dose, discontinue 3
Hypertrophic Subaortic Stenosis
- Dosage: 80-160 mg once daily (extended-release) 3
Special Populations
Elderly Patients
Elderly patients require lower doses due to decreased hepatic clearance and increased bioavailability. 4 Plasma propranolol concentrations are significantly higher in elderly patients despite similar volumes of distribution. Start at lower doses and titrate more cautiously, as aging slows tissue distribution and reduces intrinsic hepatic metabolism. 5
Hepatic Impairment
Reduce doses significantly in hepatic impairment. 5 Propranolol undergoes extensive first-pass hepatic metabolism, and impaired liver function dramatically increases bioavailability and plasma concentrations. Individual dose adjustments based on clinical response are essential.
Asthma Patients
Avoid propranolol entirely in patients with asthma or asthma history. 6, 7, 8 Propranolol (non-selective β-blocker) carries significantly increased risk of asthma exacerbation, particularly with oral and intravenous formulations. Network meta-analysis demonstrates oral timolol and IV propranolol have 3-10 times higher risk of asthma attacks compared to placebo 6. Recent FAERS database analysis confirms propranolol should be avoided in asthmatic patients 7. If β-blockade is absolutely necessary, use cardioselective agents (metoprolol, atenolol, bisoprolol) instead 8.
Critical Pitfalls to Avoid
- Never give propranolol on an empty stomach in infants - always with/after feeds 1
- Never continue propranolol during illness with reduced oral intake - hold until feeding normalizes 2
- Never use standard adult doses in elderly patients - they have 2-3x higher plasma levels 4
- Never use propranolol in asthma - use cardioselective β-blockers if β-blockade essential 6, 7
- Never rapidly discontinue in cardiovascular patients - taper over weeks to prevent rebound 3
- Never escalate to full dose in PHACE syndrome without brain imaging - risk of stroke with cerebrovascular abnormalities 2